(AOF) – Sensorion, a pioneering biotechnology company at the clinical stage, specializing in the development of new therapies to restore, treat and prevent hearing loss disorders, announces the extension for a period of five years of the framework agreement research partnership signed in 2019 with the Institut Pasteur. It grants Sensorion an exclusive license option to develop and commercialize gene therapy drug candidates from collaborative projects to address unmet medical needs in the field of hearing.
The agreement has been amended to be extended until December 31, 2028, to promote additional gene therapy development programs.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
